Xencor's oncology segment is dedicated to developing innovative antibody and cytokine therapies that target various types of cancer. This involves extensive research and development activities focused on engineering monoclonal antibodies with enhanced anti-tumor activity. Key technologies include XmAb® bispecific antibody platforms, which enable the creation of T-cell engagers and other immunotherapeutic modalities. The segment's pipeline includes clinical-stage programs such as Plamotamab, a tumor-targeted antibody in Phase I trials for non-Hodgkin lymphoma, and Vudalimab, a bispecific antibody in Phase II trials for metastatic castration-resistant prostate cancer and other solid tumors. These therapies aim to improve patient outcomes by enhancing immune responses against cancer cells and providing targeted treatment options. Future opportunities include expanding the pipeline with novel bispecific antibodies and combination therapies, as well as advancing clinical programs through regulatory approval and commercialization.

This segment focuses on the discovery and development of engineered antibodies to treat autoimmune diseases. Xencor leverages its XmAb® platform to create antibodies with improved Fc domains, enhancing their ability to modulate immune responses. Research and development efforts are directed towards developing therapies that can selectively target and suppress the immune cells responsible for autoimmune disorders. The pipeline includes XmAb564, currently in Phase I clinical trials for autoimmune diseases, and Obexelimab, which is being developed to treat various autoimmune conditions. These therapies aim to provide patients with more effective and targeted treatments, reducing the need for broad immunosuppression. Future growth potential lies in expanding the pipeline with novel antibody constructs and advancing clinical programs through regulatory approval and commercialization, addressing unmet needs in autoimmune disease treatment.

Xencor's technology platform development segment is dedicated to advancing its proprietary XmAb® engineering platform, which enables the creation of optimized antibodies and cytokines. This involves continuous research and development to improve the functionality, stability, and manufacturability of engineered proteins. Key activities include developing novel Fc domains with enhanced effector functions, creating bispecific antibodies with unique binding specificities, and optimizing cytokine variants with improved therapeutic properties. The segment's innovations support the development of new product candidates across various therapeutic areas, including oncology and immunology. Future opportunities include expanding the platform with new protein engineering technologies and leveraging it to create a diverse pipeline of innovative medicines. This segment is crucial for maintaining Xencor's competitive advantage and driving long-term growth.